Literature DB >> 22942255

Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.

Lynn M Pouliot1, Yu-Chi Chen, Jennifer Bai, Rajarshi Guha, Scott E Martin, Michael M Gottesman, Matthew D Hall.   

Abstract

Resistance to platinum-based therapies arises by multiple mechanisms, including by alterations to cell-cycle kinases that mediate G(2)-M phase arrest. In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. Overexpression of the cell-cycle kinases WEE1 and CHK1 occurred commonly in cisplatin-resistant cells. miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1. Loss-of-function and gain-of-function studies showed that miR-15 family members controlled the expression of WEE1 and CHK1. Supporting these results, we found that in the presence of cisplatin altering expression of miR-16 or related genes altered cell cycle distribution. Our findings reveal critical regulation of miRNAs and their cell-cycle-associated kinase targets in mediating resistance to cisplatin. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22942255      PMCID: PMC3500396          DOI: 10.1158/0008-5472.CAN-12-1400

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Authors:  Matthew D Hall; Mitsunori Okabe; Ding-Wu Shen; Xing-Jie Liang; Michael M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 2.  microRNA functions.

Authors:  Natascha Bushati; Stephen M Cohen
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

3.  Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

Authors:  Ryan Montano; Injae Chung; Kristen M Garner; David Parry; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

4.  Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Dorothee Wernicke; Hansjuerg Alder; Stefan Costinean; Stefano Volinia; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

5.  Role of microRNAs in drug-resistant ovarian cancer cells.

Authors:  Antonio Sorrentino; Chang-Gong Liu; Antonio Addario; Cesare Peschle; Giovanni Scambia; Cristiano Ferlini
Journal:  Gynecol Oncol       Date:  2008-09-26       Impact factor: 5.482

6.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

7.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.

Authors:  Y Shi; A Frankel; L G Radvanyi; L Z Penn; R G Miller; G B Mills
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

Review 8.  Wee1-dependent mechanisms required for coordination of cell growth and cell division.

Authors:  Douglas R Kellogg
Journal:  J Cell Sci       Date:  2003-12-15       Impact factor: 5.285

9.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Authors:  Diana M Cittelly; Partha M Das; Nicole S Spoelstra; Susan M Edgerton; Jennifer K Richer; Ann D Thor; Frank E Jones
Journal:  Mol Cancer       Date:  2010-12-20       Impact factor: 27.401

Review 10.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  53 in total

1.  MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Authors:  Xiao He; Xia Xiao; Lin Dong; Nengbin Wan; Zhengyu Zhou; Hongwu Deng; Xiefu Zhang
Journal:  Tumour Biol       Date:  2014-11-15

2.  MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

Authors:  Hanne Due; Anna Amanda Schönherz; Laura Ryø; Maria Nascimento Primo; Ditte Starberg Jespersen; Emil Aagaard Thomsen; Anne Stidholt Roug; Min Xiao; Xiaohong Tan; Yuyang Pang; Ken H Young; Martin Bøgsted; Jacob Giehm Mikkelsen; Karen Dybkær
Journal:  Blood Adv       Date:  2019-04-09

Review 3.  Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.

Authors:  Chao Liu; Qun Lin; Zhong Yun
Journal:  Radiat Res       Date:  2015-05-04       Impact factor: 2.841

Review 4.  microRNAs in cancer cell response to ionizing radiation.

Authors:  Jennifer R Czochor; Peter M Glazer
Journal:  Antioxid Redox Signal       Date:  2014-02-04       Impact factor: 8.401

5.  RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway.

Authors:  Yalan Lu; Deqiang Han; Wenjie Liu; Rong Huang; Jinhuan Ou; Xiaoqiao Chen; Xizhe Zhang; Xuezhi Wang; Shijun Li; Lin Wang; Changzheng Liu; Shiying Miao; Linfang Wang; Changwu Ma; Wei Song
Journal:  Cancer Biol Ther       Date:  2018-09-27       Impact factor: 4.742

6.  The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy.

Authors:  Jianning Song; Jie Yin; Zhigang Bai; Jun Zhang; Hua Meng; Jun Cai; Wei Deng; Xuemei Ma; Zhongtao Zhang
Journal:  Dig Dis Sci       Date:  2017-03-24       Impact factor: 3.199

7.  The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M.

Authors:  Gueorgui Kratassiouk; Linda L Pritchard; Sylvain Cuvellier; Andrii Vislovukh; Qingwei Meng; Regina Groisman; Cindy Degerny; Evgeny Deforzh; Annick Harel-Bellan; Irina Groisman
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

8.  The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line.

Authors:  Weifeng Zhao; Shuyuan Liu; Qian Dou; Changan Li; Jingpei DU; Weihua Ren
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

Review 9.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

10.  miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.

Authors:  X-H He; W Zhu; P Yuan; S Jiang; D Li; H-W Zhang; M-F Liu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.